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HGF-Promoted Motility in Primary Human
Melanocytes Depends on CD44v6 Regulated
via NF-kappa B, Egr-1, and C/EBP-beta
Sabine Damm1,2, Petra Koefinger1,2, Martina Stefan3, Christian Wels1,2, Gabor Mehes4, Erika Richtig1,
Helmut Kerl1, Marcus Otte3 and Helmut Schaider1,2
The regulation of CD44v6, a variant of the CD44 family of glycosylated adhesion molecules, through hepatocyte
growth factor (HGF) has implications for motility in primary human melanocytes. We show that exposure
of primary human melanocytes to HGF results in an increase of CD44v6 expression. Immunostaining of
melanocytic lesions revealed low cytoplasmic positivity of CD44v6 in some nevi but high membranous
expression in primary cutaneous melanomas, and cutaneous and lymph node metastases. HGF-dependent
CD44v6 regulation in melanocytes is NF-kB dependent because BAY 11-7082, an inhibitor of NF-kB activation,
but not interference with the mitogen-activated protein kinase or phosphatidylinositol 3-kinase cascade,
antagonized HGF-induced CD44v6 expression. NF-kB-mediated transcriptional regulation of CD44v6 involves
the transcription factors Egr-1 and CCAAT enhancer-binding protein-b (C/EBP-b). In gel shift assays, the initial
binding of p100/p52 NF-kB, C/EBP-b, and Egr-1 to the CD44 promoter experienced reshuffling toward increased
affinity of C/EBP-b after HGF stimulation. A blocking antibody to CD44v6 decreased HGF-induced c-Met
phosphorylation as well as enhanced random- and site-directed migration. Our data show that HGF-induced
motility in primary human melanocytes depends on c-Met–CD44v6 interaction, and that HGF-enhanced CD44v6
expression is required for motility and transcriptional upregulation of CD44v6, presumably mediated through a
complex comprising NF-kB/C/EBP-b and Egr-1.
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INTRODUCTION
Hepatocyte growth factor (HGF) is known for its mitogenic,
motogenic, and morphogenic effects and signals through
membrane-associated c-Met, a tyrosine kinase receptor
(Bottaro et al., 1991). On stimulation with HGF, c-Met,
which is expressed by epithelial cells and melanocytic cells
(Bottaro et al., 1991; Sonnenberg et al., 1993; Li et al., 2001),
is autophosphorylated at three specific tyrosine residues
(Tyr1230, Tyr1234, and Tyr1235). The two tyrosine residues
Tyr1349 and Tyr1356 are required for all biological activities
of the receptor and serve as docking sites for multiple Src
homology 2 and cytoplasmic phosphotyrosine binding
domain-containing proteins, such as Src, Shc, phosphatidy-
linositol 3-kinase (PI3K) and Grb2 (Ponzetto et al., 1994;
Royal and Park, 1995). Activation of c-Met results in cell
spreading (Birchmeier and Gherardi, 1998), loss of cadherin-
mediated cell–cell adhesion through destabilizing the
complex, comprising E-cadherin, p120, b-catenin and
a-catenin (Roura et al., 1999), and promotion of tumor
metastasis (Rong et al., 1994). E-cadherin-mediated adhesion
between melanocytes and keratinocytes is downregulated
through HGF (Li et al, 2001). In melanoma, gains in regions
of chromosome 7 including the c-Met locus are described
(Bastian et al., 1998) and metallothionein-driven expression
of HGF induced the appearance of cutaneous melanoma
with metastatic potential in transgenic mice (Otsuka et al.,
1998). In these mice, ultraviolet radiation given in a single
erythemal dose to neonatal mice leads to melanoma
development with high incidence after a relatively short
latent period (Noonan et al., 2001).
CD44 molecules are glycosylated, multifunctional, class I
transmembrane proteins associated with diverse biological
functions, such as lymphocyte homing, tumor progression,
and metastasis. Through alternative splicing, different iso-
forms are generated out of variant exons v1 to v10. The
expression of certain isoforms, especially v4-7 and v6-7, has
been attributed to confer metastatic potential to nonmeta-
static cell lines (Gu¨nthert et al., 1991; Liad and Bourguignon,
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1995). It has been recognized that complex formation of
CD44, especially v6, with c-Met is a prerequisite for the
activation of c-Met. Deletion of the cytoplasmic tail of
CD44v6 abrogates c-Met-mediated HGF signaling (Orian-
Rousseau et al., 2002). The importance of the CD44v6-c-Met
complex has been further strengthened by showing that HGF
upregulates CD44v6 expression in mouse melanoma cells
through expression of the zinc-finger transcription factor egr-1,
which in turn was responsible for transcriptional activation of
CD44v6 (Recio and Merlino, 2003).
There are few reports on the expression of CD44v6 in
human melanoma. In primary sinonasal melanomas strong
membranous expression in in situ melanomas and lack of
membranous CD44v6 expression in invasive sinonasal
melanomas has been observed. Loss of cytoplasmic
expression of CD44v6 was found to be associated with
advanced tumor stage (Regauer et al., 1999). Absence of
CD44v6 positivity in melanocytic lesions was reported in
several studies, and we found variable positive stainings in
primary melanomas (Manten-Horst et al., 1995; Ferna´ndez-
Figueras et al., 1996; Harwood et al., 1996; Schaider et al.,
1998).
On the basis of the HGF-inducing effect of UV irradiation
(Mildner et al., 2007) in keratinocytes, the endogenous HGF
expression by melanoma cells (Li et al., 2001) and the
increase of CD44v6 in mouse melanoma cells after HGF
stimulation (Recio and Merlino, 2003), we questioned, (1)
whether exposure to HGF increases CD44v6 expression in
human melanocytes and human melanoma cells and if
increased expression leads to functional consequences there-
of, (2) whether the expression correlates with progression in
melanocytic lesions, and (3) which intracellular signaling
pathways and transcription factors are potentially involved
in CD44v6 upregulation in human melanocytes and
melanoma cells.
RESULTS
CD44v6 is strongly induced in primary human melanocytes
after exposure to HGF
HGF induces upregulation of CD44v6 in murine melanoma
cells (Recio and Merlino, 2003). As HGF expression is
increased in human skin after UV irradiation (Mildner et al.,
2007), we analyzed whether HGF changes levels of CD44v6
in primary human melanocytic cells. Basal protein levels of
CD44v6 in melanocytic cells revealed a strikingly low
expression in melanocytes, but higher levels in melanoma
cells (Figure 1a), an observation partially mirrored for the
expression of c-Met (Figure 1a). The low expression of
CD44v6 protein in melanocytes as opposed to the higher
expression in melanoma cells, especially in those cell lines,
derived from superficial primary melanomas, such as
WM35 and SBcl2, was also partially confirmed by real-time
PCR (Figure 1b). Transcripts for c-Met did not differ
substantially in the cell lines analyzed, except for SBcl2
and WM9 (data not shown). Next, we determined a potential
increase of CD44v6 in human melanocytic cells after
exposure to recombinant human HGF (rhHGF). rhHGF
increased weak but significant CD44v6 transcripts in only
one melanoma cell line (WM35: 1.5-fold) and in melano-
cytes (FOM 101: 2-fold) 1 hour after exposure (Figure 2a and
see Supplementary Figure S1A online). c-Met transcripts
remained unaltered in melanocytes and melanoma cells
(Figure 2a). Immunoblotting clearly confirmed that the
exposure of melanocytes (FOM101, FOM 193), but not
melanoma cells (SBcl2, WM793, WM35, WM278, WM9,
1205Lu), to rhHGF for 8 hours led to upregulation of CD44v6
(Figure 2b and Supplementary Figure S1B). These results were
corroborated by a prolonged and continuous exposure
to HGF after transduction with an adenoviral vector encoding
the complementary DNA of human HGF (Ad.CMV.HGF)
at 20 plaque-forming units per cell (Li et al., 2001) for
48 hours (Supplementary Figure S1C). A profound increase
in CD44v6 could also be envisaged in melanocytes after
transduction with Ad.CMV.HGF but not with an adeno-
virus encoding the complementary DNA of endothelin
cell-derived lipase adenovirus by immunofluorescence
(Figure 2c). FACS analyses showed that melanocytes not
only express CD44v6 but that membranous CD44v6 is
increased after transduction with Ad.CMV.HGF (Figure 2d).
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Figure 1. Endogenous expression of CD44v6 and c-Met in melanocytes and
melanoma cell lines. (a) Western blot of the constitutive CD44v6 and c-Met
expression in melanocytes and melanoma cell lines. In total, 20 mg of total
protein was loaded per lane and samples were separated on a 7.5% SDS-
polyacrylamide gel. Blots were probed against indicated antibodies. b-Actin
was used as a loading control. (b) Semiquantitative real-time PCR of CD44v6
in melanocytes and melanoma cell lines. Values of gene expression are
calculated as relative expression compared to melanocytes. Data represent
the average of three independent experiments±SD.
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As melanoma cells endogenously produce HGF at
different levels (Li et al., 2001), we determined the effect
of a neutralizing anti-HGF antibody to basal CD44v6
expression. A decrease in CD44v6 expression was observed
in melanoma cells (Supplementary Figure S1D). These
results indicate that HGF leads to upregulation of CD44v6
in human melanocytes. Melanoma cells, which already
show increased expression of CD44v6 and produce HGF
by themselves, did not respond to additional recombinant
or adenoviral-induced production of HGF because of
autocrine HGF stimulation (Figure 2b and Supplementary
Figure S1B/C).
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Figure 2. Changes in CD44v6 expression after exposure to HGF. (a) Semiquantitative real-time PCR of CD44v6 and c-Met in melanocytes (FOM101), primary
melanoma cells (WM 793 and WM35), and metastatic melanoma cells (WM9). Cells were exposed to 50 ngml–1 rhHGF over a period of 4 hours. Values of gene
expression were calculated as relative expression compared with unexposed cells. Data represent the average of three independent experiments±SD
(**Po0.01). (b) Western blot of CD44v6 expression in melanocytes (FOM101, FOM193), primary melanoma cells (WM793 and WM35), and metastatic
melanoma cells (WM9) without or after exposure to rhHGF (50 ngml–1) after 8 hours. In total, 20 mg (FOM101, FOM193, WM793, and WM9) or 10 mg (WM35)
of total protein was loaded per lane and samples were separated on a 7.5% SDS-polyacrylamide gel. Blots were probed against indicated antibodies. b-Actin
was used as loading control. (c) Immunofluorescence of CD44v6 (green) in melanocytes (FOM101) after adenoviral transduction with Ad.CMV.HGF (20 plaque-
forming units (p.f.u.) per cell), endothelin cell-derived lipase adenovirus (EDL-Ad) (20 p.f.u. per cell), or vector control (LacZ) for 48 hours. Isotype-specific
mouse IgG1 was used as control. Nuclei were stained with Hoechst (blue) and merged with CD44v6 staining. Bar¼ 50mm. (d) Flow cytometry of membranous
CD44v6 in melanocytes (FOM101) after adenoviral transduction with Ad.CMV.HGF (20 p.f.u. per cell) or vector control (LacZ) for 48 hours. Grey: unlabeled
control; black: vector control; red: Ad.CMV.HGF.
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Low expression of CD44v6 in nevi
The low basal expression of CD44v6 in melanocytes
prompted us to examine the CD44v6 expression in
melanocytic lesions by immunohistochemistry in more detail.
In 12 nevi membranous staining patters were lacking,
however, three congenital nevi showed a weak cytoplasmic
expression in nevus nests near the basal membrane
(Figure 3a). Nevus cells in the dermis were negative for
CD44v6. In primary cutaneous melanomas, however, a
moderate cytoplasmic and membranous staining was found
in most tissue samples. Significant intratumoral heterogeneity
was observed in melanoma nests with absent or positive
staining (Figure 3b). Only 2 out of 10 primary melanomas
showed no staining at all. Membranous staining pattern was
even more prominent in cutaneous and sub-cutaneous
metastases, with an increase in intensity in nests of melanoma
cells (data not shown). A further increase in membranous and
cytoplasmic staining was found in lymph node metastases
(Figure 3c). Strong membranous staining was focally identi-
fied with a homogenous expression throughout the entire cell
population. In contrast, visceral metastases of primary
cutaneous melanoma were completely negative (Figure 3d),
with the exception of a metastasis to the cerebrum (not
shown). In determining immunoreactivity of melanocytic
lesions by an immunoreactive score, a significant difference
in staining intensity was found in nevi compared with
primary melanomas, as well as cutaneous and lymph node
metastasis (Figure 3e). The same accounted for the lack of
staining in visceral metastases.
NF-jB induces CD44v6 transcription in primary human
melanocytes
Downstream signaling pathways of c-Met comprise activa-
tion of NF-kB, PI3K, and mitogen-activated protein kinase
(MAPK) (Cho and Kim, 2003; Recio and Merlino, 2003; Fan
et al., 2005). To determine the pathways involved in
CD44v6 activation by rhHGF, inhibitors of NF-kB (BAY11-
7082), PI3K (Ly294002), or MAPK (PD98059) were used as
single compounds (Figure 4a). Only inhibition of NF-kB, but
not PI3K or MAPK, led to a significant downregulation of
rhHGF-induced CD44v6 expression in human melanocytes,
and combinations with BAY11-7082 confirmed this finding.
In melanoma cells, like in WM35, inhibition of all three
pathways led to a decrease of CD44v6 (Supplementary
Figure S2A). To further analyze NF-kB-dependent regu-
lation of transcription factors, consensus sequences and
binding sites in the promoter region of CD44v6 were
identified for Egr-1, CCAAT enhancer-binding protein
(C/EBP)-b, and GATA2, but not for NF-kB itself reaching
1,000 nucleotides upstream of the transcription initiation site.
Activation of all three transcription factors has been reported
to be linked directly or indirectly to NF-kB (Shen et al., 1997;
Perkins, 1997; Komine et al., 2000; Minami and Aird, 2001;
Kleemann et al., 2003; Thyss et al., 2005; Kim et al., 2007).
Within 15minutes, protein levels of Egr-1 and C/EBP-b
increased significantly after exposure to rhHGF and returned
to endogenous levels within 8hours; no change was observed
for GATA2 after 15minutes up to 24hours after exposure
(Figure 4b). In the primary melanoma cell lineWM35, however,
increased levels of Egr-1 and C/EBP-b sustained for the period of
24hours (Supplementary Figure S2B), indicating continuous
stimulation through endogenous HGF. To determine signaling
pathways important for Egr-1 and C/EBP-b regulation, all three
inhibitors (BAY11-7082, Ly294002, and PD98059) were used.
Egr-1 protein level was increased 15minutes after exposure to
rhHGF. Pre-incubation with HGF-neutralizing antibody or PI3K
inhibitor (Ly294002) prior to HGF stimulation lowered the
increase of Egr-1. Antagonists of MAPK (PD98059) as well as
NF-kB (BAY11-7082) signalling completely blocked the in-
crease of Egr-1 (Figure 4c). Decreased expression of C/EBP-b
and GATA2, however, was observed by inhibiting NF-kB,
MAPK, or PI3K (Figure 4c). These results point to a crucial role
for NF-kB in mediating HGF-induced expression of CD44v6
and, subsequently, initiation of transcription potentially via
Egr-1 and C/EBP-b.
Egr-1 binds to the consensus sequence 50-GCG
(T/G)GGGCG-30, but binding to motifs differing in 1 or 2 bp
has also been shown (Molnar et al., 1994; Pospelov et al.,
1994; Maltzman et al., 1996). Two potential Egr-1-binding
sites were found at bp 600 and 301 of the human CD44
promoter. Each of these motifs differs from the consensus
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Figure 3. Immunohistochemistry of melanocytic lesions. (a–d)
Immunohistochemical analyses of paraffin-embedded sections of human nevi
(a), primary melanoma (b), lymph-node metastasis (c), and visceral metastasis
to the lung (d) for expression of CD44v6. Epithelial cells showed always a
strong CD44v6 positivity (a, b, epidermis; d, lung epithelial cells). In c, cells
negative for CD44v6 are part of the lymphocytic tissue. Original
magnification is  20 and inserts are 40 (a) and  60, respectively.
Bar¼50 mm. (e) Immunohistochemical staining of CD44v6 in melanocytic
lesions. IRS (immunoreactivity score): multiplying the percentage of positive
cells (0–100) with staining intensity (0–2) divided by 10.
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binding site by at least 1 bp. As Egr-1 binds with low affinity
to the site at bp 301 of the CD44 promoter but not to the
site at bp -600 (Maltzman et al., 1996), we focused on the
binding site at bp -301. We found six potential consensus
C/EBP-b-binding sites (50-T(T/G)NNGNAA(T/G)-30) (Pope
et al., 1994) in the human CD44 promoter. Information
regarding the binding properties of C/EBP-b to the CD44
promoter and the effect of HGF on the binding properties of
Egr-1 and C/EBP-b is not available. Four fragments of 197 bp
(C/EBP-b P1: two C/EBP-b-binding sites), 292 bp (C/EBP-b P2:
three C/EBP-b-binding sites), 213 bp (C/EBP-b P3: one C/EBP-
b-binding site), and 253 bp (Egr-1: one C/EBP-b-binding site,
one Egr-1-binding site) labeled 50 with the fluorescent dye
Cy3 were generated (Materials and Methods). Nuclear
extracts of FOM101 were incubated with specific DNA-
probes encoding the binding region of Erg-1 and C/EBP-b.
Egr-1 and C/EBP-b-binding regions were derived from
sequence analysis of the CD44 promoter region. After
incubation, gel shift assays were performed and shifts were
envisaged for all four DNA-probes. Gel shifts were blotted for
subsequent analysis of C/EBP-b, Egr-1, NF-kB p100/p52, and
NF-kB p65 by immunoblotting. As expected Egr-1 bound to
the Egr-1-binding site (at bp -301), but surprisingly Egr-1
binding was not enhanced by HGF (Figure 4d). C/EBP-b
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bound to the allocated binding sites of the CD44 promoter,
and C/EBP-b binding was enhanced by HGF (Figure 4d). It
has been reported that Egr-1 and NF-kB are able to interact
with C/EBP-b (Shen et al., 1997; Komine et al., 2000; Zhang
et al., 2003) and, indeed, we observed Egr-1 as well as NF-kB
p100/p52 but not NF-kB p65 at the C/EBP-b-binding sites
(Figure 4d and Supplementary Figure S2C). Interestingly, after
stimulation with HGF binding of C/EBP-b was not only
increased but Egr-1 and NF-kB p100/p52 binding decreased
(Figure 4d). These findings suggest that C/EBP-b together with
Egr-1 and NF-kB form a complex binding to the C/EBP-b
promoter site. After stimulation with HGF most of Egr-1 and
NF-kB may dissociate from C/EBP-b, resulting in higher
binding of C/EBP-b to the CD44 promoter.
HGF-induced motility in human melanocytes requires CD44v6
Phosphorylation of c-Met is dependent on the presence of
CD44v6, which forms a complex with c-Met in carcinoma as
well as primary human cell lines (Orian-Rousseau et al.,
2002). To see whether this also applies for human melano-
cytes, c-Met phosphorylation and the influence of CD44v6
on c-Met phosphorylation was determined. As expected,
an increase in phosphorylation of c-Met was observed
2.5minutes after exposure to rhHGF, reaching a plateau of
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Figure 5. CD44v6 is required for c-Met activation and cell migration. (a) Western blot of phosphorylated c-Met (Tyr 1234/1235) in melanocytes (FOM101)
after exposure to rhHGF (50 ngml–1) for 15minutes. A neutralizing antibody for HGF was added at 1mgml–1 or a CD44v6 blocking antibody was added at
15mgml–1 1hour before rhHGF exposure. In all, 20mg of total protein was loaded per lane and samples were separated on a 7.5% SDS-polyacrylamide gel. Blots
were probed against indicated antibodies. Tubulin was used as a loading control. Numbers indicate changes in percentage of control. Bands were quantified by
densitometry. Data were normalized to tubulin and presented as % of control. (b) Wound healing assays of melanocytes (FOM101) after treatment with rhHGF
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represent the average of three independent determinations±SD (& Control, HGF,’ HGFþHGF neutralizing antibody; HGFþCD44v6 blocking antibody).
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4-fold activation at 15minutes (data not shown). To test for
CD44v6 dependence, the significant increase in phosphory-
lated c-Met 15minutes after exposure to HGF was probed in
the presence of a neutralizing antibody for HGF or a blocking
antibody to CD44v6. Both antibodies diminished protein
levels of phoshorylated c-Met at Tyr1234/1235 impressively
(Figure 5a). This underscores the importance of CD44v6 for
proper activation of c-Met by HGF in human melanocytes.
On the basis of our findings of NF-kB predominance in
regulating CD44v6 (Figure 4a), the influence of pathway
inhibitors on c-Met phosphorylation was examined (Supple-
mentary Figure S3A). Both Ly294002 and PD98059 reduced
phospho-c-Met comparable to the neutralizing antibody
for HGF, whereas BAY11-7082 decreased phosphorylated
c-Met to control levels. This indicates that the signaling
through PI3K and MAPK is hampered in the presence of
the inhibitors and may explain the lack of efficacy in altering
CD44v6 protein levels (Figure 4a). To further analyze the
functional consequences of HGF-induced elevation of
CD44v6 expression, random- and site-directed migration
assays were performed. Microscopic examination at 16
and 24 hours revealed a significant delay in wound closure
of melanocytes exposed to a neutralizing antibody of
HGF or a blocking antibody to CD44v6 compared with
cells exposed to rhHGF alone (Figure 5b). This finding
was corroborated by analyzing on site-directed migration.
Cellular migration toward rhHGF was significantly increased
compared with that of controls. The CD44v6 blocking
antibody abrogated cell migration in the presence of rhHGF
(Figure 5c). The observed changes in migration were not
related to an increase in proliferation because proliferation of
melanocytes was not increased in rhHGF exposed melano-
cytes (Figure 5d).
DISCUSSION
As a result of UV irradiation cytokines are released from
keratinocytes, which subsequently induce HGF secretion in
fibroblasts. One of the consequences of HGF expression is
the delivery of pro-survival effects (Beuret et al., 2007), and
the downregulation of E-cadherin in human melanocytes (Li
et al., 2001). Still, the relevance of HGF for alternating
melanocyte homeostasis is poorly understood.
HGF upregulates CD44v6 expression in mouse melanoma
cells (Recio and Merlino, 2003), but there are few reports on
the expression, regulation, and function of CD44v6 in human
melanocytic cells. In this study, we show that CD44v6 is
expressed in human melanocytic cell lines albeit with
higher levels in melanoma cell lines. The cell culture data
correlate with immunohistochemical CD44v6 analyses in
nevi and radial growth phase melanomas. However, for some
of the melanoma-derived cell lines protein and messenger
RNA expression levels are discordant, which may be
explained by DNA sequence variations effecting transcription
and translation, translational regulation, or differences in
protein in vivo half-lives (Nie et al., 2006). Melanoma cells
did not respond to additional HGF because of an already
existing constitutive autocrine loop. Immunostaining of
melanocytic lesions revealed no membranous staining
pattern but a low staining of CD44v6 only in congenital
nevi and a near absence in visceral metastases of primary
cutaneous melanomas, but high membranous expression in
primary cutaneous melanomas, cutaneous, and lymph node
metastases, which confirms our finding in melanocytic cells.
This is in contrast to most of the studies on the expression of
CD44v6 in melanoma tissue, in which a lack of immunos-
taining for CD44v6 was reported (Manten-Horst et al., 1995;
Ferna´ndez-Figueras et al., 1996; Harwood et al., 1996;
Ranuncolo et al., 2002). However, we previously observed
CD44v6 positivity in nests of subepidermal melanoma cells
of some primary melanomas (Schaider et al., 1998). As
melanoma cell lines, which originate from lymph node
metastasis, like WM9, express CD44v6, we argue that the
positive staining observed in tissue is realistic.
By using inhibitors for the main signaling pathways of
HGF, we have shown that CD44v6 is exclusively regulated
through NF-kB. The reason for the selective inhibition by
NF-kB may be related to the constitutive activations of the
RAS/MEK/ERK and the PI3K/AKT signaling pathways in
melanoma cells compared to melanocytes (Satyamoorthy
et al., 2003; Meier et al., 2007). To analyze the direct
transcriptional regulation of NF-kB, we searched for a
consensus sequence at the CD44 promoter, but were unable
to detect corresponding binding sites. Instead, consensus
sequences for three transcription factors (Egr-1, C/EBP-b, and
GATA2) were found. These are directly or indirectly activated
by NF-kB (Perkins, 1997; Kleemann et al., 2003; Komine
et al., 2000; Kim et al., 2007; Thyss et al., 2005; Minami and
Aird, 2001; Shen et al., 1997). In addition to Egr-1, our data
show that C/EBP-b protein levels increased after exposure to
HGF, suggesting an involvement of both transcription factors
in CD44 transcriptional regulation.
Protein levels of NF-kB are not influenced by HGF, but
rather it causes a nuclear translocation of NF-kB within
5minutes (Fan et al., 2005). After translocation, nuclear
NF-kB can bind to and activate the Egr-1 and C/EBP-b
promoter (Shen et al., 1997; Thyss et al., 2005). In human
melanocytes, Egr-1 bound to the described binding site at bp
-301 in the CD44 promoter but the binding did not increase
after HGF stimulation. Whether C/EBP-b binds to the CD44
promoter is unknown; we determined six potential binding
sites in the CD44 promoter. C/EBP-b bound to the allocated
binding sites and the affinity clearly increased after HGF
stimulation. Interestingly, Egr-1 and NF-kB p100/p52 could
also be detected at the C/EBP-b-binding sites. These data left
us with the idea that a complex comprising NF-kB p100/p52,
C/EBP-b, and Egr-1 exists. It has been reported that NF-kB
serves as a co-activator and forms a complex with C/EBP-b,
which is based on a physical interaction of both partners
(Shen et al., 1997; Komine et al., 2000). Therefore, we
speculate that C/EBP-b is not only regulated through
NF-kB but both may form a complex like in keratinocytes
and are necessary for increased CD44v6 expression in human
melanocytes. Similarly to NF-kB, Egr-1 specifically interacts
with C/EBP-b in human hepatoma cells to activate the
human low-density lipoprotein receptor. There is no
direct binding site for Egr-1 in the promoter region of the
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low-density lipoprotein receptor but one binding site for
C/EBP-b, and both are important for increased low-density
lipoprotein receptor expression (Zhang et al., 2003). HGF
stimulation leads to an increase of C/EBP-b binding to the
CD44 promoter but Egr-1 and NF-kB binding decrease. Thus,
it seems that Egr-1 and NF-kB dissociate from C/EBP-b
after stimulation with HGF and more C/EBP-b is recruited.
After stimulation with HGF-binding affinities of NF-kB and
Egr-1 in the complex are modulated and decrease; the affinity
of C/EBP-b, however, increases substantially (Figure 6).
Signalling of c-Met through HGF depends on the function
of CD44v6 because it is required to organize a ternary
complex among c-Met, HGF, and CD44v6, which is a
prerequisite for c-Met activation (Orian-Rousseau et al.,
2002). CD44 monitors the cellular environment through its
N-terminus that contains binding sites for hyaluronan.
Importantly, these CD44-hyaluronan interactions are regu-
lated by E-cadherin. Cells that express high levels of
E-cadherin reduce the binding between hyaluronan and
CD44 (Xu and Yu, 2003). We have shown that HGF
downregulates E-cadherin in melanocytes (Li et al., 2001),
opening a new perspective for HGF-mediated effects with
respect to CD44v6, in which HGF facilitates melanocyte
independence from keratinocytes. Downregulated E-cadher-
in may allow for interaction of CD44(v6) with hyaluronic
acid in melanocytes, which present with endogenously
low CD44v6 but high E-cadherin levels. Elevated levels
of CD44v6 expression precede the E-cadherin downregulat-
ing effect of HGF. The requirement of CD44v6 for c-Met
activation and the increased invasion after CD44-hyaluronan
binding together with the immediate upregulation of
CD44v6 in response to HGF in human melanocytes
suggests a vital role of CD44v6 at the very beginning in
melanomagenesis.
MATERIALS AND METHODS
Cell lines and cell culture
The human primary melanoma cell lines WM35, SBcl2, WM793,
WM278 and metastatic melanoma cell lines WM9, WM164, 451Lu,
and 1205Lu were cultured in RPMI 1640 (Invitrogen, Paisley, UK)
supplemented with 2% (v/v) fetal bovine serum, 2% (w/v)
L-glutamine, and 2% antibiotics (cell lines were provided by
Dr M Herlyn, Wistar Institute, PA). Human melanocytes (FOM101,
FOM193; Supplementary Figure S3B), derived from human foreskin,
were cultured in human melanocyte growth medium (PromoCell
GmbH, Heidelberg, Germany). All cells were maintained at 37 1C in a
humidified atmosphere containing 5% CO2. Cells were washed with
phosphate-buffered saline after 24hours of starvation, except for
melanocytes, and then exposed to rhHGF protein (R&D Systems,
Minneapolis, MN) in serum and protein free media up to 24hours at
50ngml–1. Where specified, the cells were incubated before HGF
activation with anti-CD44v6 antibody (15mgml–1) or anti-HGF anti-
body (1mgml–1) for 1h or with Inhibitors PD98059 (25mM), Ly294002
(25mM), and BAY11-7082 (10mM) for 30minutes. Afterwards, whole
cell extracts were generated at indicated time intervals. Where
indicated, subconfluent melanocytes and melanoma cells were
transduced with 20 plaque-forming units per cell of each adenoviral
vector for 4hours at 37 1C. Viral suspension was then replaced
with culture medium. After additional 48hours, cytoplasmic extracts
(Nuclear Extract Kit; Active Motive, Rixenart, Belgium) were generated.
Adenoviral vectors
The adenoviral vector (Ad.CMV.HGF) coding for human HGF and
an adenoviral vector-containing LacZ (vector control) were kindly
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Figure 6. A model for regulatory mechanisms implicated in HGF-mediated activation of CD44v6. Binding affinities to the CD44 promoter before and
after stimulation with HGF. Initially C/EBP-b/Egr-1/NF-kBp100/p52 bind to C/EBP-b-binding sites of CD44. After HGF stimulation, Egr-1 and NF-kB dissociate
from C/EBP-b and more C/EBP-b is recruited to the binding sites.
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provided by Dr Yoshiteru Murofushi (Kurume University, Japan). The
recombinant endothelin cell-derived lipase adenovirus coding for
human endothelial cell-derived lipase was kindly provided by Dr
Sasa Frank (Medical University Graz, Austria).
Antibodies and inhibitors
Primary antibody against CD44v6 (VFF-18; 1:200) was purchased
from Bender MedSystems (Vienna, Austria). Anti-Egr-1 (C-19; 1:800),
anti-C/EBP b (H-7; 1:200), and anti c-Met (C-12, 1:200) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho c-Met
(3D7; 1:1000) and anti-NF-kB p100/p52 (1:1000) was purchased
from Cell Signaling Technology (Danvers, MA), anti-GATA 2
(2mgml–1) was from Abcam plc. (Cambridge, UK) and anti-NF-kB
p65 (NF-12; 1:1000), anti-Tubulin (B512; 1:2000), and anti-Beta-
Actin (AC-15; 1:5000) were purchased from Sigma-Aldrich (St Louis,
MO). For immunofluorescence, primary antibody against CD44v6
(VFF-7; 1:75, Santa Cruz Biotechnology) was used. For flow
cytometry a FITC-conjugated antibody against CD44v6 (VFF-7) from
Serotec (Oxford, UK) was used. Inhibitors PD98059 (25 mM),
Ly294002 (25 mM), and BAY11-7082 (10 mM) were purchased from
Calbiochem (Merck Chemicals, Nottingham, UK). Anti-CD44v6
antibody (2F10) was used as blocking antibody for CD44v6 and anti-
HGF (24612) was used as neutralizing antibody for HGF; both were
purchased from R&D Systems.
Immunoblotting
To generate whole cell extracts, cells were washed three times in
phosphate-buffered saline and lysed in ice-cold RIPA-Buffer (Sigma)
containing Protease Inhibitor Cocktail (Roche Diagnostics GmbH,
Mannheim, Germany) and Phosphatase Inhibitor Cocktail (Roche
Diagnostics GmbH) for 20minutes. For immunoblotting, cytoplas-
mic extracts or whole cell extracts were used. Protein concentration
was measured using the Bradford protein assay (Bio-Rad Labora-
tories GmbH, Munich, Germany). Equal protein aliquots were
loaded, separated on 7.5% SDS-polyacrylamide gels, transferred to
polyvinylidene difluoride membranes and probed with specific
primary antibodies. To detect the signal, peroxidase-conjugated
secondary antibody was added. Proteins were visualized using
enhanced chemiluminescence reagents (Amersham, Arlington
Heights, IL) and exposed to X-ray film. For quantification, the blots
were analyzed in a Chemi Doc TM XRS Universal Hood (Bio-Rad).
Extraction of RNA, reverse transcription, and real-time
semiquantiative PCR analysis
RNA was isolated (RNeasy Extraction Kit, Quiagen, Hilden,
Germany) from human melanocytes and human melanoma cell
lines. In all, 1mg of total RNA was reverse transcribed using a
complementary DNA synthesis kit (QuantiTec Reverse Transcription
Kit, Quiagen, Hilden, Germany), according to the manufacturer’s
protocol. Real-time PCR was performed in a 7,300 real-time PCR
system (Applied Biosystems, Foster City, CA) using SYBR Green
Master Mix (Applied Biosystems). Primers for CD44v6 were forward,
50-GCAACTCCTAGTAGTACAACGGAAGA-03, reverse, 50-CGATAT
CCCTCATGCCATCTGT-30, for c-Met forward, 50-AACCATTTCAAC
TGAGTTTGCTGTT-30, reverse, 50-TTCACGGTAACTGAAGATGCTT
GT-30 and for glyceraldehyde-3-phosphate dehydrogenase forward,
50-CTGCCCCCTCTGCTGATG-30, reverse, 50-GCTGATGATCTTGA
GGCTGTTG-30.
Immunofluorescence
Melanocytes were grown on poly-D-lysine-eight-well chamber
slides to 50–60% confluence and were transduced with 20 plaque-
forming units per cell of each adenoviral vector for 4 hours at 37 1C.
Viral suspension was then replaced with culture medium. After an
additional 48hours cells were fixed with 4% (w/v) paraformaldehyde
at room temperature for 10minutes, permeabilized with tris-buffered
saline containing 0.5% Triton X-100 and 0.25% Tween 20 for
15minutes at room temperature and blocked with Image iT FX Signal
Enhancer (Invitrogen) for 30minutes at room temperature in a humid
chamber. After blocking, the cells were washed and primary antibody
for CD44v6 (Santa Cruz Biotechnology) was added and incubated
overnight at 4 1C. To detect the signal, Alexa Flour-conjugated
secondary antibody was added. Cells were then washed, mounted
with aqueous mounting medium (DakoCytomation, Glostrup, Den-
mark) and examined using a Nikon TS-100 fluorescence microscope
(Nikon Instruments Europe B.V., Amstelveen, The Netherlands).
Flow cytometry
Melanocytes were grown to 50–60% confluence and were trans-
duced with 20 plaque-forming units per cell of each adenoviral
vector for 4 hours at 37 1C. Viral suspension was then replaced with
culture medium. After an additional 48 hours, cells were harvested
by Accutase (Sigma) and 1 106 cells were fixed with 4% (w/v)
paraformaldehyde at room temperature for 10minutes. Cells were
resuspended in phosphate-buffered saline, incubated with FITC-
conjugated CD44v6 antibody for 45minutes at room temperature,
washed once with phosphate-buffered saline and analyzed using
a FACSCalibur flow cytometer (BD Biosciences, Heidelberg,
Germany) at a wavelength of 488 nm.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue was stained after antigen-
retrieval with DAKO target retrieval solution pH9 (DAKOCytoma-
tion, Glostrup, Denmark), following the manufacturer’s guidelines.
For subsequent CD44v6 visualization the monoclonal antibody
VFF-18 (Bender MedSystems) was used (1:150; 6.5 mgml–1) in
combination with the EnVision System HRP DualLink Mouse/Rabbit
(DAKOCytomation) detection system. Appropriate positive and
negative control slides were analysed in parallel. Scoring of tissue
slides was performed independently by two investigators; percentage
of positive cells and the intensity of staining were graded from 0 to
3þ : 0, no staining; 1þ , weak positive staining; 2þ , moderate
positive staining; and 3þ , strong staining. An immunoreactive score
was obtained by multiplying the percentage of positive cells with
staining intensity divided by 10.
Electrophoretic mobility shift assays
Band-shift assays were performed with Cy3-labeled sequences of
CD44 including C/EBP-b or Egr-1-binding sequences (four oligonu-
cleotides, C/EBP-b P1 -3396 to -3200, C/EBP-b P2 -2326 to -2035, C/
EBP-b P3 -562 to -350, and Egr-1 -500 to -248) as probe. Primers for
C/EBP-b P1 were forward, 50-TTGCAAAGCACTTTCACACC-30,
reverse, 50-CCATCCCAACCACAGAAGTT-30, for C/EBP-b P2 for-
ward, 50-TCTCTGGACAAGCCATGTTCT-30, reverse, 50-CCAAACCC
TATTATGGCTGCT-30, for C/EBP-b P3 forward, 50-AACCCAGAGAT
CTTGCTCCA-30, reverse, 50-GTCGGGGAACCTGGAGTGT-30, and
for Egr-1 forward, 50-CTGAACCCAATGGTGCAAGGT-30, reverse,
www.jidonline.org 1901
S Damm et al.
HGF Promotes Motility in Human Melanocytes
50-CCGCAGAGGTTTTAAGAAGTAGCA-30. Melanocytes (FOM101)
were left unstimulated or stimulated with HGF for 15minutes and
nuclear extracts were generated. Nuclear extracts (10mg) were
incubated with Cy3-labeled double-strand oligonucleotides for
15minutes at 37 1C in binding buffer (10mM Tris (pH 7.5), 50mM
NaCl, 1mM dithiothreitol, 0.1mM EDTA, 5% (v/v) glycerol) with 2mg
of poly(dI-dC). After incubation, the reaction samples were separated
by non-denaturing PAGE. The separated DNA-protein complexes
were transferred to a polyvinylidene difluoride membrane and
probed with C/EBP-b, Egr-1, NF-kB p100/p52, or NF-kB p65
antibodies by immunoblotting as described above.
Scratch assay
To test for random migration, wound-healing assays were
performed by plating Melanocytes in six-well plates reaching
80% confluence. Cells were exposed to rhHGF protein (50 ngml–1)
in serum and protein-free medium for 8 hours. Where indicated,
cells were treated before HGF activation with anti-CD44v6
antibody (15 mgml–1) or anti-HGF antibody (1 mgml–1) for 1 hour.
After 8 hours, a scratch or wound was made using a sterile
pipette tip. Plates were washed with medium to remove all detached
cells and incubated in human melanocytes growth medium up to
24 hours. Photographs of cells invading the scratch were taken
at indicated time intervals using an Olympus IX51 inverted
microscope (Olympus Europe GmbH, Hamburg, Germany). Assays
were performed in triplicate for each condition.
Migration assay
The migration assay was performed using Cell Culture Inserts with
PET membrane (8mm pore size; BD Falcon, BD Biosciences
Heidelberg, Germany). Melanocytes were treated with rhHGF
protein (50 ngml–1) in serum and protein-free medium for 8 hours.
For inhibition, cells were pre-incubated with anti-CD44v6 antibody
(15 mgml–1) or anti-HGF antibody (1mgml–1) for 1 hour. Eight hours
after HGF stimulation, cells were harvested by Trypsin/EDTA buffer
and 4 104 cells in serum-free medium were added to the upper
compartment of the Cell Culture Inserts. The lower compartment
was filled with serum- and protein-free medium containing
50 ngml–1 rhHGF protein. After 16 hours of incubation at 37 1C,
the upper surface of the membrane was wiped with a cotton swab to
remove non-migratory cells. Cells that migrated to the bottom side of
the membrane were fixed with methanol, stained with Toluidine
blue for 10minutes and the membrane was washed twice with
water. Membranes were placed on a glass slide, and from each
membrane six fields were counted using an optical microscope.
Assays were performed in triplicate for each condition.
Proliferation assay
Melanocytes were plated in six-well plates (7.5 104 cells per well)
and exposed to rhHGF protein (50 ngml–1) in serum- and protein-
free medium for 8 hours. Where specified, cells were treated
before HGF activation with anti-CD44v6 antibody (15 mgml–1) or
anti-HGF antibody (1 mgml–1) for 1 hour. After 8 hours of incubation,
the medium was changed to fresh human melanocyte growth
medium. Cells were counted with a Neubauer counting cell
chamber at indicated time intervals. The cell cytotoxicity was
examined using Trypan blue exclusion assay. Assays were performed
in triplicate for each condition.
Statistics
Statistical analyses were performed using Student’s t-test. Results are
calculated as the mean±SD of three different experiments. P-values
o0.05 were considered significant.
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